Medicines and Healthcare products Regulatory Agency (MHRA) signs Memorandum of Understanding (MOU) with its counterpart body in India.

The Medicines and Healthcare products Regulatory Agency (MHRA) has signed a Memorandum of Understanding (MOU) with its counterpart body in India on Monday 05th October 2015. This agreement will increase collaboration between the 2 countries in the area of medicines and medical devices with the aim of further improving public safety in the 2 countries.

This is the first MOU agreed with the Central Drugs Standard Control Organisation (CDSCO), part of the Ministry of Health and Family Welfare of Republic of India and was signed by Dr Gyanendra Nath Singh, India’s Drugs Controller General, and MHRA Chairman, Professor Sir Michael Rawlins. It provides a formal agreement between the 2 organisations, and strengthens relations between the UK and Indian governments.

For more information on the above please click here

Read more

CMA ENCOURAGES COMPETITIVE MARKETS WITH NEW POLICY GUIDELINES

The CMA on 15 September 2015 has published guidelines to help policymakers assess the potential impact that their proposals could have on competition.

Through lower prices and greater choice the Competitive markets have benefited consumers, by encouraging suppliers to create new products and different ways of bringing products to markets.

Government intervention in markets - including through regulation and legislation - can have the unintended side effect of restricting competition in a number of ways. These Competition and Markets Authority (CMA) guidelines provide policymakers with advice on how to assess whether proposals could affect competition adversely. The guidelines also suggest ways in which proposals could be re-designed in order to support competition.

For more information on the above please click here

Read more